Quarterly ResultAug 5, 2026, 04:14 PM
McKesson Q1 Adj. EPS $9.93 (+20%); Raises FY27 Guidance to $44.20-$45.00
AI Summary
McKesson Corporation reported strong first-quarter fiscal 2027 results, with consolidated revenues increasing 8% to $105.4 billion and Adjusted Earnings per Diluted Share growing 20% to $9.93. Following this performance, the company raised its full-year fiscal 2027 Adjusted EPS guidance range to $44.20-$45.00. McKesson also announced a 15% increase in its quarterly dividend to $0.94 per share and returned $2.6 billion to shareholders. Progress was also noted in the planned separation of its Medical-Surgical Solutions segment, which has been named Wellverse.
Key Highlights
- Raised Fiscal 2027 Adjusted EPS guidance range to $44.20-$45.00 (from $43.80-$44.60).
- Consolidated revenues for Q1 increased 8% to $105.4 billion.
- Adjusted Earnings per Diluted Share for Q1 increased 20% to $9.93.
- Board of Directors approved a 15% increase to the quarterly dividend, to $0.94 per share.
- Returned $2.6 billion to shareholders, including $2.25 billion through accelerated share repurchase.
- North American Pharmaceutical segment Adjusted Operating Profit increased 19%.
- Oncology & Multispecialty segment Adjusted Operating Profit increased 41%.
- Medical-Surgical Solutions segment named Wellverse as part of planned separation.
Price Impact
More from MCK